Retinitis Pigmentosa Clinical Trial
Official title:
Observational Study of the Argus® II Retinal Prosthesis System
The Argus II Retinal Implant is a revolutionary new device, which offers vision to patients who are blind from retinal degeneration - retinitis pigmentosa. These patients have no alternatives. Patients typically can achieve ambulatory vision.
This study is an investigator-sponsored, observational, controlled, prospective,
single-center study. The purpose of this current study is how it affects people's visual
function and activities of daily living and to collect additional data on Argus II users in
order to monitor the System's safety. In addition, data about the long-term reliability of
the System will be gathered.
The Argus II retinal implant will be surgical implanted into patients who are blind but the
surgical procedure is not a part of this observational study. Our hypothesis is that the
visual results in our hands will be comparable to those reported in the FDA study. We will
use the results of this study to plan future enhancements to the service and to explore the
use of the device for other blinding conditions.
;
Observational Model: Case-Only, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT01432847 -
Cell Collection to Study Eye Diseases
|
||
| Completed |
NCT04983914 -
Retrospective NIS to Evaluate the Patient Benefit of TES
|
||
| Recruiting |
NCT03845218 -
Retinitis Pigmentosa Clinical Measures and Repeatability Testing of Potential Outcome Measures
|
||
| Completed |
NCT00231010 -
Molecular Genetics of Retinal Degenerations
|
||
| Active, not recruiting |
NCT04611503 -
PDE6A Gene Therapy for Retinitis Pigmentosa
|
Phase 1/Phase 2 | |
| Completed |
NCT02909985 -
Visual Activity Evoked by Infrared in Humans After Dark Adaptation
|
N/A | |
| Recruiting |
NCT01914913 -
Clinical Study to Evaluate Safety and Efficacy of BMMNC in Retinitis Pigmentosa
|
Phase 1/Phase 2 | |
| Completed |
NCT01949623 -
Biomarkers In Retinitis Pigmentosa (BIRP)
|
N/A | |
| Completed |
NCT01835002 -
Transcorneal Electrical Stimulation - Multicenter Safety Study
|
N/A | |
| Completed |
NCT00407602 -
Argus® II Retinal Stimulation System Feasibility Protocol
|
N/A | |
| Completed |
NCT00515814 -
Retina Implant Pilot Trial to Evaluate Safety & Efficacy in Blind Patients Having Degenerated Photo-receptors
|
N/A | |
| Completed |
NCT00100230 -
DHA and X-Linked Retinitis Pigmentosa
|
Phase 2 | |
| Active, not recruiting |
NCT00378742 -
Repository for Inherited Eye Diseases
|
||
| Terminated |
NCT05085964 -
An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa
|
Phase 2 | |
| Recruiting |
NCT05805007 -
Safety and Tolerability Study of Gene Editing Drug ZVS203e in Participants With Retinitis Pigmentosa
|
Early Phase 1 | |
| Recruiting |
NCT05909488 -
Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II
|
Phase 2/Phase 3 | |
| Recruiting |
NCT06291935 -
Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene
|
Phase 1 | |
| Recruiting |
NCT03078309 -
The Effects of Cannabis on Visual Functions in Healthy and Retinitis Pigmentosa Patients
|
Early Phase 1 | |
| Completed |
NCT04238858 -
Effects of Subtenon-injected Autologous Platelet-rich Plasma on Visual Functions in Eyes With Retinitis Pigmentosa
|
N/A | |
| Active, not recruiting |
NCT01680510 -
The Effect of Oral Administration of 9-cis β Carotene Rich Powder of the Alga Dunaliella Bardawil
|
Phase 1/Phase 2 |